FDA approves second Alzheimer’s drug that may slow onset of disease | Alzheimer’s
Federal health authorities gave approval Tuesday to an experimental new drug that has been shown to delay the onset of Alzheimer’s disease in trials. Donanemab, made by Eli Lilly, is the second drug to win Food and Drug Administration (FDA) approval to treat patients showing early symptoms of the disease, most notably cognitive impairment. Last … Read more